



### **NormOxys Announces Series A Financing\***

BOSTON, MA –August 31, 2007 – NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased cells, today announced that it has secured a Series A financing of \$8 million. Index Ventures of Geneva, Switzerland led the round.

NormOxys has a proprietary technology platform to develop a new class of small molecule drugs, oxyrens, to treat a broad range of diseases where therapeutic benefit can be obtained through an increased, regulated delivery of oxygen to hypoxic tissues. Potential clinical indications include cancer, cardiovascular diseases, anemia, Alzheimer's' disease, stroke and diabetic retinopathy.

As part of this transaction, Drs. Francesco De Rubertis and Michele Ollier of Index Ventures will become members of the NormOxys board of directors, joining existing board members Claude Nicolau, PhD, NormOxys Chief Scientific Officer and Co-Founder; Jean-Marie Lehn, PhD, Nobel Laureate in Chemistry and NormOxys Co-Founder; and Conrad Bletzer, Jr., Esq., NormOxys President and Co-Founder.

#### **About NormOxys**

NormOxys is developing a novel class of small molecule drugs, oxyrens, which enhance the body's ability to deliver oxygen more efficiently to diseased tissues with oxygen deficiency. This new class of drugs can be potentially developed in a broad range of clinical indications where therapeutic benefit can be obtained through an increased, regulated delivery of oxygen to hypoxic tissues, such as cancer, cardiovascular diseases, anemia, Alzheimer's' disease, stroke and diabetic retinopathy. The company is based in Boston, MA and was founded by Prof. Claude Nicolau, PhD, and Nobel Laureate Prof. Jean-Marie Lehn, PhD, based on their groundbreaking investigations in chemistry and cellular biophysics. To learn more about NormOxys, please visit the Company's website at [www.normoxys.com](http://www.normoxys.com).

*\*This press release has been updated to reflect a change in the corporate name.*